ImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment
I'm PortAI, I can summarize articles.
ImmuneOnco Biopharmaceuticals has completed enrollment of 104 patients in a Phase III trial for IMM01 (Timdarpacept) targeting chronic myelomonocytic leukemia (CMML). The company aims to enroll a total of 132 patients by March 2026 for interim analysis. The drug, in combination with azacitidine, received orphan-drug designation from the FDA in November 2023. ImmuneOnco holds global rights to IMM01.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments